Fungal Infections

Latest News

Echinocandin Dosing Considerations in Obese Patients: A Review
Echinocandin Dosing Considerations in Obese Patients: A Review

November 18th 2024

Obesity significantly impacts the pharmacokinetics (PK) of antifungal drugs like echinocandins, including volume of distribution (Vd) and clearance. However, despite these PK differences, current clinical evidence generally does not support the need for universal dose adjustments in obese patients. Clinicians should consider personalized dosing based on patient characteristics, infection severity, and specific drug properties due to echinocandins' favorable safety profiles.

Infection Control: AP Technology's Impact on Reducing HAIs and AMR Pathogens
Infection Control: AP Technology's Impact on Reducing HAIs and AMR Pathogens

November 6th 2024

Photohydrolysis Technology Achieves Reduction in Fungal Colony-Forming Units and C auris In Hospital Settings
Photohydrolysis Technology Achieves Reduction in Fungal Colony-Forming Units and C auris In Hospital Settings

November 5th 2024

Defining the Characteristics of Breakthrough Invasive Fungal Infections in Hematologic Disorders
Defining the Characteristics of Breakthrough Invasive Fungal Infections in Hematologic Disorders

October 31st 2024

Antifungal Begins Phase 3 Trial
Antifungal Begins Phase 3 Trial

October 7th 2024

More News

© 2024 MJH Life Sciences

All rights reserved.